Schering-Plough Acquires Phase II HBV Agent In $110 Mil. Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Compound utilizes Metabasis' HepDirect technology to enable higher concentrations of the drug in the liver, and lower concentrations elsewhere, Schering says.